Organ transplantation stands as a sign of hope for those battling organ failure, yet the chance of rejection continues to haunt the success of these life-saving procedures. Daniel Pavicic Meier, an experienced pharmaceutical consultant, recently shared a LinkedIn post highlighting a new therapy that proves effective against kidney transplant failures.
Our Practice Lead, Teresa Gorecki, responded to the LinkedIn post by echoing sentiments shared by many. In her post, she emphasizes the vitality of ongoing research into preventing and treating rejection following organ transplantation. She also highlights the launch of a therapy that she had the honor of supporting, which also assisted with organ transplantation failures 30 years ago.
Read below to learn more about Daniel Pavicic Meier and Teresa Gorecki’s insights into discoveries that can battle organ transplantation failures.

Table of Contents
The Challenge of Antibody-Mediated Rejection (AMR)
In a recent LinkedIn post, Daniel Pavicic Meier delves into the persistent challenge posed by antibody-mediated rejection (AMR), one of the leading causes of kidney transplant failures. Despite extensive efforts, finding a sustainable solution to combat AMR has remained a recurring issue.
Felzartamab: A Novel Therapeutic Avenue
Daniel continues to explain how a breakthrough emerges from felzartamab, a monoclonal CD38 Antibody originally designed to combat multiple myeloma. This innovative therapy, with its unique ability to influence immune reactions, has garnered interest in transplantation medicine to potentially combat AMR directly.
Research Methodology and Key Findings
Meier’s post sheds light on a meticulously conducted study published in the esteemed New England Journal of Medicine, which evaluated felzartamab’s efficacy in mitigating AMR following kidney transplants. The study employed a rigorous, randomized, double-blind, and placebo-controlled design, which yielded promising results for the researchers.
Implications and Hope for the Future
As mentioned previously, AMR is one of the greatest threats to organ transplantations, often leading to organ failure and the need for additional interventions. The advent of felzartamab not only holds promise for kidney transplant recipients but also raises hopes for reducing rejection in other organ transplants, such as heart or lung transplants. This would also potentially advance xenotransplantation, which uses pig organs.
A Global Collaborative Effort
This groundbreaking research, a collaborative endeavor involving institutions worldwide, marks a significant milestone in transplantation medicine. Conducted across esteemed institutions such as MedUni Vienna, University Hospital Vienna, Charité Hospital in Berlin, University Hospital in Basel, and the University of Alberta, Canada, this interdisciplinary Phase II study paves the way for future advancements.
Towards Validation and Beyond
As the research community looks into the future, plans for a multicenter Phase III study are underway. This study will aim to validate and build upon the promising outcomes observed in this ongoing endeavor. This signifies a leap towards transforming transplantation outcomes globally and improving all types of transplants.
Teresa’s Comments & Organ Transplantation Importance
Teresa shared her insights on this recent accomplishment by congratulating the team on their new therapeutic accomplishment and sharing her support in launching Orthoclone OKT3 30 years ago. Orthoclone OKT3 stopped cellular rejection after kidney, liver, and/or heart transplants.
As we celebrate this triumph, Teresa Gorecki’s advocacy for new research continues to grow. The journey towards overcoming organ rejection is far from over. Despite this, we inch closer to a future where organ transplantation is not just a medical procedure but a glimpse of hope for countless lives with each new medical breakthrough.
Click here for the link to the original LinkedIn post by Daniel Pavicic Meier.
For more information, fill out the form below.